Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Bain, C. C., Scott, C. L., Uronen-Hansson, H., Gudjonsson, S., Jansson, O., Grip, O., Guilliams, M., Malissen, B., Agace, W. W., & Mowat, A. M. (2013) · Mucosal Immunology · doi:10.1038/mi.2012.89 · Cited by 943
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 821
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685
Lübbe, A. S., Bergemann, C., Riess, H. B., Schriever, F., Reichardt, P., Possinger, K., Matthias, M., Dörken, B., Herrmann, F., Gürtler, R., et al. (1996) · PubMed · Cited by 652
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W., Wang, J., Wang, X., & Fu, Y.-X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.004 · Cited by 472
Is autoimmunity the Achilles' heel of cancer immunotherapy?
June, C. H., Warshauer, J. T., & Bluestone, J. A. (2017) · Nature Medicine · doi:10.1038/nm.4321 · Cited by 445
Sagiv-Barfi, I., Kohrt, H. E. K., Czerwinski, D. K., Ng, P. P., Chang, B. Y., & Levy, R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500712112 · Cited by 444
Schlecker, E., Stojanovic, A., Eisen, C., Quack, C., Falk, C. S., Umansky, V., & Cerwenka, A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201018 · Cited by 438
Therapies from Fucoidan: An Update
Fitton, J., Stringer, D., & Karpiniec, S. (2015) · Marine Drugs · doi:10.3390/md13095920 · Cited by 418
Chung, J. E., Tan, S., Gao, S. J., Yongvongsoontorn, N., Kim, S. H., Lee, J. H., Choi, H. S., Yano, H., Zhuo, L., Kurisawa, M., et al. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.208 · Cited by 412
Villadolid, J. J., & Amin, A. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.06.06 · Cited by 409
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy
Fan, Y., & Moon, J. (2015) · Vaccines · doi:10.3390/vaccines3030662 · Cited by 275
Hydrodynamics of magnetic drug targeting
Voltairas, P. A., Fotiadis, D. I., & Michalis, L. K. (2002) · Journal of Biomechanics · doi:10.1016/s0021-9290(02)00034-9 · Cited by 275
Natural and Induced T Regulatory Cells in Cancer
Adeegbe, D. O., & Nishikawa, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00190 · Cited by 248
Liu, J., Zhang, N., Li, Q., Zhang, W., Ke, F., Leng, Q., Wang, H., Chen, J., & Wang, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019495 · Cited by 245
Fucoidan as a Marine Anticancer Agent in Preclinical Development
Kwak, J.-Y. (2014) · Marine Drugs · doi:10.3390/md12020851 · Cited by 220
Li, Y., & Kurlander, R. J. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-104 · Cited by 207
Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy
Goldinger, S. M., Stieger, P., Meier, B., Micaletto, S., Contassot, E., French, L. E., & Dummer, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2872 · Cited by 202
Jin, J.-O., Zhang, W., Du, J.-Y., Wong, K.-W., Oda, T., & Yu, Q. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099396 · Cited by 160
Hsu, H.-Y., Lin, T.-Y., Hwang, P.-A., Tseng, L.-M., Chen, R.-H., Tsao, S.-M., & Hsu, J. (2013) · Carcinogenesis · doi:10.1093/carcin/bgs396 · Cited by 141
Immune and hemorheological changes in Chronic Fatigue Syndrome
Brenu, E., Staines, D., Baskurt, O. K., Ashton, K. J., Ramos, S. B., Christy, R., & Marshall‐Gradisnik, S. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-1 · Cited by 119
The emerging role of immune checkpoint inhibition in malignant lymphoma
Hude, I., Sasse, S., Engert, A., & Bröckelmann, P. J. (2017) · Haematologica · doi:10.3324/haematol.2016.150656 · Cited by 108
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
Carlo, M. I., Voss, M. H., & Motzer, R. J. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.103 · Cited by 97
Sun, J. T., Sun, J., Song, B., Zhang, L., Shao, Q., Liu, Y., Yuan, D., Zhang, Y., & Qu, X. (2016) · Scientific Reports · doi:10.1038/srep35855 · Cited by 95
Johnston, A. P. R., Kamphuis, M. M. J., Such, G. K., Scott, A. M., Nice, E. C., Heath, J. K., & Caruso, F. (2012) · ACS Nano · doi:10.1021/nn3010476 · Cited by 90
Shaping Magnetic Fields to Direct Therapy to Ears and Eyes
Shapiro, B., Kulkarni, S., Nacev, A. N., Sarwar, A., Preciado, D. A., & Depireux, D. A. (2014) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-105206 · Cited by 88
Chiang, C., Shen, Y., Liu, J., Shyu, W., & Chen, S. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600479 · Cited by 38
Self-citationGorlova, O. Y., Martin, J. M., Rueda‐Medina, B., Koeleman, B. P. C., Ying, J., Teruel, M., Díaz-Gallo, L.-M., Broen, J. C. A., Vonk, M. C., Simeón‐Aznar, C. P., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-s1-o1 · Cited by 32
Interface-mediated fabrication of bowl-like and deflated ballon-like hollow carbon nanospheres
Zhang, H., & Li, X. (2015) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2015.04.027 · Cited by 17
Cited by
Reactive Oxygen Species (ROS)-Based Nanomedicine
Yang, B., Chen, Y., & Shi, J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00626 · Cited by 2,443
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 682
Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
Peng, S., Xiao, F., Chen, M., & Gao, H. (2022) · Advanced Science · doi:10.1002/advs.202103836 · Cited by 441
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Sang, W., Zhang, Z., Dai, Y., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 405
Metadata
- Authors
- Chiang, C.-S., Lin, Y.-J., Lee, R., Lai, Y.-H., Cheng, H.-W., Hsieh, C.-H., Shyu, W.-C., & Chen, S.-Y.
- Venue
- Nature Nanotechnology
- Published
- 2018-05-14
- Volume
- 13
- Issue
- 8
- Pages
- 746-754
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- OpenAlex
- W2799307831
- Cited by
- 283
- References
- 42
- FWCI
- 12.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.